OverviewSuggest Edit

Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
TypePublic
Founded1978
HQCambridge, MA, US
Websitebiogen.com
Employee Ratings4.1
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)7,400(-5%)
Job Openings462
Revenue (FY, 2019)$14.4 B(+7%)
Share Price (Dec 2020)$244.1 (-1%)
Cybersecurity ratingCMore

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

Chief Executive Officer and Director
Susan Alexander

Susan Alexander

Executive Vice President, Chief Legal Officer and Secretary
Stelios Papadopoulos

Stelios Papadopoulos

Chairman of the Board
Michael McDonnell

Michael McDonnell

Executive Vice President, CFO
Alphonse Galdes

Alphonse Galdes

Executive Vice President, Pharmaceutical Operations and Technology
Ginger Gregory

Ginger Gregory

Executive Vice President, Chief Human Resource Officer
Show more

Biogen Office Locations

Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 35 other locations
Cambridge, MA, US (HQ)
225 Binney St
Morrisville, NC, US
5000 Davis Dr
Waltham, MA, US
203 Crescent St #303
Washington, DC, US
601 Pennsylvania Ave NW #720
Weston, MA, US
133 Boston Post Rd
Vicente López, AR
7th Floor, Av. del Libertador 350
Show all (39)

Biogen Financials and Metrics

Biogen Revenue

Embed Graph
View revenue for all periods
Biogen's revenue was reported to be $14.38 b in FY, 2019 which is a 6.9% increase from the previous period.
USD

Revenue (Q3, 2020)

2.7b

Market capitalization (3-Dec-2020)

37.6b

Closing stock price (3-Dec-2020)

244.1

Cash (30-Sept-2020)

2.2b

EV

35.7b
Biogen's current market capitalization is $37.6 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

12.3b13.5b14.4b

Revenue growth, %

10%7%

Cost of goods sold

1.6b1.8b2.0b

Gross profit

10.6b11.6b12.4b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

2.8b3.1b3.1b3.1b3.4b3.4b3.5b3.6b3.6b3.5b3.7b2.7b

Cost of goods sold

384.6m366.2m370.0m446.0m421.0m460.8m602.0m476.3m430.0m454.3m411.1m

Gross profit

2.4b2.7b2.7b2.7b2.9b3.0b2.9b3.1b3.2b3.1b3.3b

Gross profit Margin, %

86%88%88%86%87%87%83%87%88%87%89%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

1.6b1.2b2.9b

Accounts Receivable

1.8b2.0b1.9b

Inventories

902.7m929.9m804.2m

Current Assets

7.9b7.6b8.4b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

924.0m1.2b1.5b4.1b1.3b2.4b2.2b1.7b2.3b2.6b2.4b2.2b

Accounts Receivable

1.5b1.6b1.6b1.9b2.0b2.0b2.1b2.0b1.9b2.1b2.1b2.0b

Inventories

921.6m936.5m1.0b890.8m931.7m916.6m770.2m776.7m751.8m858.8m952.7m1.0b

Current Assets

6.9b7.1b7.6b10.2b7.4b8.7b8.9b7.9b8.4b8.0b8.5b7.8b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

2.7b4.5b5.9b

Depreciation and Amortization

1.1b1.0b680.6m

Inventories

(94.5m)(52.1m)(19.2m)

Cash From Operating Activities

4.6b6.2b7.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

747.5m1.6b2.8b1.2b2.1b3.5b1.4b2.9b4.4b1.4b3.0b3.7b

Depreciation and Amortization

512.0m814.6m992.0m168.9m340.4m686.9m121.1m238.1m567.6m119.9m232.8m366.8m

Inventories

(46.2m)(85.3m)(170.3m)(2.6m)(40.1m)(31.9m)(129.0m)(108.7m)(47.3m)(62.2m)(188.2m)(270.6m)

Cash From Operating Activities

235.2m1.4b3.0b1.5b2.6b4.3b1.5b3.4b5.1b1.5b3.4b4.6b
USDQ1, 2017

Debt/Equity

0.6 x

Debt/Assets

0.3 x

Financial Leverage

1.8 x
Show all financial metrics

Biogen Operating Metrics

FY, 2016FY, 2017FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020

Phase I Trials Products

4 4 7 6 8 9 9 9 11

Phase I/II Trials Products

1

Phase II Trials Products

10 12 13 13 12 12 11 10 10

Phase III Trials Products

2 3 4 3 5 5 6 6 6
Show all operating metrics

Biogen Acquisitions / Subsidiaries

Company NameDateDeal Size
Nightstar TherapeuticsMarch 04, 2019$800 m
AliveGenJuly 25, 2018$27.50 m
Karyopharm TherapeuticsJanuary 25, 2018$10 m
Remedy PharmaceuticalsMay 18, 2017$120 m
Convergence PharmaceuticalsFebruary 14, 2014$675 m
StromedixFebruary 14, 2014$75 m
TysabriFebruary 28, 2013
Syntonix PharmaceuticalsJanuary 04, 2007$120 m
FumapharmMay 31, 2006
Conforma TherapeuticsMay 03, 2006$150 m
Show more

Biogen Revenue Breakdown

Embed Graph

Biogen revenue breakdown by business segment: 15.9% from Anti-CD20 Therapeutic Programs, 79.1% from Product Revenues and 4.9% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Biogen Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Biogen Online and Social Media Presence

Embed Graph

Biogen Company Culture

  • Overall Culture

    B

    72/100

  • CEO Rating

    C-

    65/100

  • Compensation

    A+

    84/100

  • Diversity

    A

    81/100

Learn more on Comparably

Biogen News and Updates

Sage Therapeutics to receive $1.525 billion in cash in deal with Biogen to jointly develop depression, tremor therapies

Biogen Inc. and Sage Therapeutics Inc. said Monday they have agreed to jointly develop therapies to treat depression and movement disorders in a deal in which Biogen will give Sage $1.525 billion in cash. The money will be split between an upfront payment of $875 million and a $650 million equity …

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

CAMBRIDGE, Mass., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), p…

BIIB INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securitie…

ROSEN, A TOP RANKED LAW FIRM, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm – BIIB

NEW YORK, Nov. 22, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the “Class Period”) of the important January 12, 2021 lead plaintiff deadline…

Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)

INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application for SB11, a proposed biosimilar referenci…

TOP RANKED ROSEN LAW FIRM Files First Securities Class Action Lawsuit Against Biogen Inc.; Encourages Investors with Losses in Excess of $500K to Contact the Firm - BIIB

NEW YORK, Nov. 13, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the "Class Period")....
Show more

Biogen Blogs

Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership

Biogen earns top scores on areas including access to medicine, talent attraction, innovation management and climate performance and reporting In 2013 Biogen became the 1 st U.S. biotech company to appear on the DJSI World Index 2020 marks the 8 th consecutive year that Biogen was listed among top

Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting

Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting Content Import Tue, 11/03/2020 - 07:30 Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting …

Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020

Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020 jo-en.bautista… Mon, 11/02/2020 - 13:59 Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020 …

Biogen to Report Third Quarter 2020 Financial Results October 21, 2020

Cambridge, Mass. — Biogen Inc. (Nasdaq: BIIB) today announced it will report third quarter 2020 financial results Wednesday, October 21, 2020, before the financial markets open.  Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

Statement about the FDA advisory committee on aducanumab

Statement about the FDA advisory committee on aducanumab Ray.Beron@west.com Tue, 09/29/2020 - 11:44 Statement about the FDA advisory committee on aducanumab September 29, 2020 at 4:06 PM EDT This release is a backfill from a News Wire In…

Reactive Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab

Reactive Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab Ray.Beron@west.com Tue, 09/29/2020 - 11:43 Reactive Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab September 29, 2020 at 4:06 PM EDT …
Show more

Biogen Frequently Asked Questions

  • When was Biogen founded?

    Biogen was founded in 1978.

  • Who are Biogen key executives?

    Biogen's key executives are Michel Vounatsos, Susan Alexander and Stelios Papadopoulos.

  • How many employees does Biogen have?

    Biogen has 7,400 employees.

  • What is Biogen revenue?

    Latest Biogen annual revenue is $14.4 b.

  • What is Biogen revenue per employee?

    Latest Biogen revenue per employee is $1.9 m.

  • Who are Biogen competitors?

    Competitors of Biogen include Covance, Sanofi Genzyme and EMD Serono.

  • Where is Biogen headquarters?

    Biogen headquarters is located at 225 Binney St, Cambridge.

  • Where are Biogen offices?

    Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 35 other locations.

  • How many offices does Biogen have?

    Biogen has 39 offices.